BNP Paribas Financial Markets Has $86,000 Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL)

BNP Paribas Financial Markets raised its holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 97.0% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 15,074 shares of the biotechnology company’s stock after acquiring an additional 7,421 shares during the quarter. BNP Paribas Financial Markets’ holdings in Anavex Life Sciences were worth $86,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AVXL. Nwam LLC bought a new position in shares of Anavex Life Sciences in the 3rd quarter valued at about $5,172,000. Charles Schwab Investment Management Inc. grew its stake in Anavex Life Sciences by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 14,892 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Anavex Life Sciences during the 3rd quarter worth approximately $134,000. Atria Investments Inc acquired a new position in shares of Anavex Life Sciences during the 3rd quarter worth approximately $76,000. Finally, Balentine LLC bought a new stake in shares of Anavex Life Sciences during the 3rd quarter worth approximately $115,000. 31.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. D. Boral Capital reissued a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research note on Monday, November 25th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Anavex Life Sciences in a research note on Wednesday, November 27th.

Anavex Life Sciences Stock Down 5.6 %

Shares of NASDAQ AVXL opened at $8.69 on Thursday. Anavex Life Sciences Corp. has a twelve month low of $3.25 and a twelve month high of $10.45. The business’s 50 day moving average price is $7.55 and its two-hundred day moving average price is $6.11. The company has a market cap of $736.88 million, a PE ratio of -17.38 and a beta of 0.73.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.